The SELECT trial showed that semaglutide 2.4 mg (Wegovy) reduces cardiovascular risk in adults with established cardiovascular disease and either overweight or obesity, leading to an FDA-approved indication for reducing cardiovascular risk in this population
Besides reducing appetite and increasing calorie expenditure, Semaglutide GLP-1 improves insulin sensitivity, allowing better glucose uptake by cells and lowering blood sugar levels
For instance, a 2020 study with 35 participants taking liraglutide reported reduced cravings for sweet, salty, savory, and fatty foods, along with an increased sense of fullness
Common side effects of taking tirzepatide include nausea, vomiting, diarrhea, decreased appetite, abdominal pain or discomfort, and constipation